Bioinvent International AB
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 4 name spellings.
1
Ending by 2030
Mar 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 23, 2027The maintenance fee for Human ANTI-FGFR4 Antibody (US 10,358,498) comes due Jan 23, 2027. Unpaid by Jul 23, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 10 of 10
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,592,347 | Method for screening anti-ligand libraries for identifying anti-ligands specific for differentially and infrequently expressed ligands In force (reinstated) · From the USPTO record | In force (reinstated) | From the USPTO record | |
| US 10,191,049 | Screening methods and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 12,344,673 | Medicaments, Uses and Methods In force · High confidence | In force | High confidence | |
| US 10,358,498 | Human ANTI-FGFR4 Antibody In force · High confidence | In force | High confidence | |
| US 10,765,738 | Combination of ANTI-FGFR4-ANTIBODY and Bile Acid Sequestrant In force · High confidence | In force | High confidence | |
| US 11,648,310 | Combination of ANTI-FGFR4-ANTIBODY and Bile Acid Sequestrant In force · Low confidence | In force | Low confidence | |
| US 10,995,143 | Combination of Human ANTI-FGFR4 Antibody and Sorafenib In force · High confidence | In force | High confidence | |
| US 12,441,805 | Novel Antagonistic ANTI-TNFR2 Antibodies In force · High confidence | In force | High confidence | |
| US 12,139,547 | Novel Agonistic Anti TNFR2 Antibody Molecules In force · High confidence | In force | High confidence | |
| US 12,371,498 | Novel Combination and Use of Antibodies In force · High confidence | In force | High confidence |
Also on record, not counted in the 10: 1 patent in force now held by others · 10 lapsed for an unpaid fee · 8 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
11 pending · 10 no status recorded